What the Pandemic Is Telling Us About Science, Politics, and Values
By Daniel Sarewitz,
Slate
| 03. 24. 2020
For the past 30 years, I have tried to make sense of the interactions between science and politics, especially the challenge of making decisions under conditions of uncertainty and disagreement. Why—despite huge and ever-expanding bodies of relevant scientific research—is it so impossible to resolve disagreements around climate change, nuclear energy, mammograms, K–12 public education, chemicals in the environment, genetically modified organisms, nutritional guidelines, trade policy, and on and on? Why, despite all the research and expertise, do the opposing sides of these debates remain fixed in their values and interests, certain in their own version of the facts and immovable in their sense of what should or should not be done?
Thanks to the COVID-19 pandemic, the relation between science and politics is now at the center of the world stage. The novel coronavirus offers up a powerful and extremely clear lesson about the appropriate role of science in helping to guide us toward a better future—a lesson that sharply contradicts standard thinking about science and politics. Above all, we are learning that science’s place in politics is determined not...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...